Risankizumab
- Generic Name
- Risankizumab
- Brand Names
- Skyrizi 150 Mg Dose Pack, Skyrizi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1612838-76-2
- Unique Ingredient Identifier
- 90ZX3Q3FR7
- Background
Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. Risankizumab is being investigated for...
- Indication
Risankizumab is indicated to treat:
- Associated Conditions
- Moderate plaque-type psoriasis, Psoriasis, Psoriatic Arthritis, Severe Plaque Type Psoriasis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, severe Psoriasis Vulgaris (Plaque Psoriasis), Severe, active Crohn´s Disease
- Associated Therapies
- -
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 507
- Registration Number
- NCT02672852
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 214
- Registration Number
- NCT02443298
- Locations
- 🇬🇧
Wishaw General Hospital, Wishaw, United Kingdom
🇳🇱HagaZiekenhuis, Den Haag, Netherlands
🇵🇱Univ. Hospital in Krakow,Pulmonology Clinical Dept, Krakow, Poland
Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT02203851
BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 159
- Registration Number
- NCT02047110
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath